This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Eli Lilly's Pipeline Springs a Leak, but Don't Worry

NEW YORK (TheStreet) -- Never one to shy away from a contrarian position, back in October I rushed to the defense of Eli Lilly (LLY) following some harsh words and several downgrades from the Street. Investors had many concerns.

Chief among them were worries about Lilly's pipeline of drugs in development and production. Although I wasn't necessarily Lilly's biggest fan at the time, I didn't agree with the idea the stock, which then traded at around $49 per share, would see the 20% downside suggested by Jefferies analyst Jeffrey Holford, who cut his price target to $40.

Holford cited pipeline fears, which have been a known issue with Lilly for some time. But I believed this was already priced into the stock. Lilly had retraced 15% in the couple of months before Holford's note.

Fast-forward two months later: The Food and Drug Administration (FDA) announced it approved generic versions of Cymbalta, Lilly's blockbuster anti-depressant drug that accounts for more than 25% of Lilly's revenue. Even more interesting: Unlike most generic approvals, FDA announced that it had, in fact, granted not one, but six approvals to, among others, Teva Pharmaceuticals (TEVA).

But here's the thing -- the market didn't flinch. Everyone knew the so-called "patent cliff" was coming. Lilly is still trading at around $49 per share, as of the Monday close -- the same price from back in October when I told you not to worry. It seems that I was right the Street had already priced in the competition from generics.

Having said that, Lilly is still not out of the woods yet. These new generic rivals must still compete on price.  I believe it is safe to say their prices will be much cheaper than Lilly's. Even so, it will take several quarters before Lilly will feel the impact on its consolidated results.

Here's another thing that no one is talking about: the fact that the FDA issued six approvals may actually play into Lilly's favor. Not only must these generics compete with Lilly's branded drug, but they must also compete with each other on price. The production of these new generics will be based on the profits these companies are able to produce.

Stock quotes in this article: LLY, TEVA, MRK, PFE 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,424.85 +162.29 1.00%
S&P 500 1,862.31 +19.33 1.05%
NASDAQ 4,086.2250 +52.0640 1.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs